Low dose Medidur FA safe and effective in DME

Article

Low doses of Alimera Sciences' Medidur FA provide visual acuity improvements and reduce the risk of ocular side effects commonly associated with corticosteroids, when administered to diabetic macular oedema (DME) patients, according to the three-month interim results of the first human pharmacokinetic (PK) study.

Low doses of Alimera Sciences' Medidur FA provide visual acuity improvements and reduce the risk of ocular side effects commonly associated with corticosteroids, when administered to diabetic macular oedema (DME) patients, according to the three-month interim results of the first human pharmacokinetic (PK) study.

If approved by the FDA, Alimera intends to market the product under the trade name Iluvien. Each Illuvien intravitreal insert, which is delivered with a 25-gauge needle, has been designed to provide a sustained therapeutic effect for 24-36 months, depending on the dose of the corticosteroid, fluocinolone acetonide, administered within the insert.

The 36-month, open-label, Phase II PK study, which is running simultaneously with the pivotal Phase III FAME trial (Fluocinolone Acetonide in Diabetic Macular Edema), was designed to assess the systemic exposure to the corticosteroid as well as to provide information on the safety and efficacy of Iluvien in DME patients.

Thirty-seven patients were enrolled into the study in total, 20 of whom received low dose Iluvien (approximately 0.23 µg/day), whilst the remaining 17 patients received high dose Iluvien (approximately 0.45 µg/day).

At three months, 20% of the low dose patients and 18% of the high dose patients showed an improvement in best corrected visual acuity of 15 letters or more and a significant decrease in retinal thickness was noted in both groups. Although no intraocular pressure (IOP) related side effects were apparent in the low dose group, 12% of high dose patients experienced an increase in IOP of more than 30 mmHg. Only one incidence of cataract was reported in the high dose group.

Alimera will now continue to assess the results of the PK study at quarterly intervals.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
Related Content
© 2025 MJH Life Sciences

All rights reserved.